Why the study?
Do direct-acting oral anticoagulants reduce bleeding and ischemic events compared to vitamin K antagonists or aspirin in patients with chronic coronary syndromes?
Do direct-acting oral anticoagulants reduce bleeding and ischemic events compared to vitamin K antagonists or aspirin in patients with chronic coronary syndromes?
Answers are grounded in this paper and cite their sources.
DOACs offer a safer alternative to VKAs regarding bleeding in patients with AF undergoing PCI, and low-dose rivaroxaban combined with aspirin improves ischemic outcomes in high-risk patients with chronic coronary syndromes.
inhibitor was non-inferior to a VKA regimen on bleeding outcomes (major bleeding or non-major clinically relevant non-major bleeding) after a 12-month follow-up (HR 0.83; 95% CI [0.65-1.05]; p=0.001 for non-inferiority; p=0.1154 for superiority). Meta-analysis of these four trials confirmed the safety of DOACs regarding bleeding outcomes, but showed a trend toward stent thrombosis for dual antithrombotic therapy using DOACs versus triple antithrombotic therapy using VKAs. DOACs may show promise in the management of high-risk patients with chronic coronary syndromes. In these patients, rivaroxaban 2.5 mg twice daily in addition to aspirin was shown to reduce the composite outcome of cardiovascular death, stroke or MI compared to aspirin alone (HR 0.76; 95% CI [0.66-0.86]; p<0.001). All-cause death, cardiovascular death and stroke were also significantly lower. This benefit was at the cost of an increase in non-fatal bleeding.
No takes yet. Share an insight, caveat, or question.
Sorbets et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: